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Abstract
Objectives. aPL are present in between 20 and 30% of patients with SLE. They can cause vascular events (VE) or
pregnancy morbidity. aCL and anti-beta-2-glycoprotein I (anti-b2GPI) are measured in clinical practice. Domain I (DI) of
b2GPI is the main site for aPL binding. We investigated the prevalence of IgG anti-DI, aCL and anti-b2GPI antibodies in
early SLE and their association with mortality and development of VE.
Methods. Samples from 501 patients with SLE that had been obtained and stored early during their disease were
tested for IgG anti-DI, aCL and anti-b2GPI antibodies by ELISA. LA status and history of VE were obtained by reviewing
medical records. KaplanMeier analysis was used to investigate mortality and occurrence of VE, comparing groups with
and without aPL in early disease.
Results. Of 501 patients, 190 (38%) had at least one of these aPL, of whom 112 had anti-DI alone. Of 276 patients with
complete vascular history, 83 had experienced VE. The 39 patients who were double or triple-ELISA-positive for any
combination of the three aPL were more likely to have or develop lupus anticoagulant (P<0.0001) than those who were
single-ELISA-positive or negative. In KaplanMeier analysis, they showed a trend towards developing more VE (P= 0.06).
Conclusion. IgG anti-DI antibodies were present in early serum samples from 29% of patients and were more common
than IgG aCL or anti-b2GPI. There was some evidence suggesting that double or triple-ELISA-positivity for these anti-
bodies identified a group with worse outcomes.
Key words: systemic lupus erythematosus, anti-phospholipid antibodies, mortality, vascular thrombosis, beta-
2-glycoprotein I, anti-phospholipid syndrome, anti-DI
Rheumatology key messages
. IgG anti-phospholipid antibodies were present in 38% of early-disease samples from patients with SLE.
. IgG antibodies to domain I (DI) of beta-2-GPI were the commonest specificity detected.
. Positivity for >1 of IgG anti-cardiolipin, anti-beta-2-GPI and/or anti-DI was associated with worse outcomes.
Introduction
aPL were first described in the context of SLE and multiple
reports over the last 30 years have shown that they are
present in the blood of 2030% of patients with SLE [1].
Only a minority of these patients, however, develop vas-
cular thrombosis and/or pregnancy morbidity, which are
the cardinal features of the APS [2]. There are three tests
for aPL used commonly in clinical practice; the aCL
ELISA, the anti-beta-2-glycoprotein I (anti- b 2GPI)
ELISA and the LA test [2]. In many lupus clinics, these
tests are requested routinely for screening in all newly
diagnosed patients with SLE. It is not clear, however,
what to do in the case of patients who have positive
aPL results at diagnosis, whereas they have not yet suf-
fered thrombosis or pregnancy loss. It is recognized that
features such as high-titre positivity for IgG aCL and/or
anti-b2GPI, and triple positivity for LA, aCL and anti-
b2GPI [3, 4] are all factors that increase risk of thrombosis
[5], but not to the extent that routine anticoagulation for
those with these serological profiles is recommended as
primary prophylaxis to prevent thrombosis.
b2GPI consists of five domains of which the N-terminal
domain (Domain I, DI) is believed to contain the major
immunological epitope [6, 7]. Thus, assays for anti-DI
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antibodies have been proposed as an alternative test that
could have greater predictive power for occurrence of
thrombosis and pregnancy morbidity [710]. However,
there is little evidence concerning the prevalence of anti-
DI antibodies early in the disease course of patients with
SLE and whether presence of these antibodies with or
without aCL and anti-b2GPI positivity delineates patient
groups with higher risk of mortality or vascular events
(VE) over many years of follow-up. The aim of this study
was to investigate these unanswered questions.
We therefore extracted the first available stored serum
sample for 501 patients with SLE, tested these samples
for IgG aCL, IgG anti-b2GPI and IgG anti-DI, and com-
pared these serological profiles to clinical outcomes of
death or VE during the subsequent follow-up period.
Methods
At University College London Hospital (UCLH), the spe-
cialist SLE clinic has been running since 1979 and has
followed over 600 patients. Stored serum samples from
these patients have been kept at 80C. All patients
entered into the lupus cohort at UCLH fulfil the American
College of Rheumatology criteria for SLE [11]. The earliest
available serum samples from 501 patients were retrieved
from storage and used in the ELISAs. For over 90% of
patients, this earliest sample was obtained within two
years of diagnosis.
Clinical information on VE and LA positivity was ob-
tained from patient records and from interviews with pa-
tients (for those still alive and under follow-up in the clinic)
with informed consent and with ethics approval from the
London Hampstead Research Ethics Committee
(Reference Number 12/LO/0373).
VE were defined as including deep venous thrombosis,
pulmonary embolism, catastrophic APS, myocardial in-
farction, stroke and coronary heart disease (the last two
required proof by appropriate imaging).
LA assay
LA is assessed at UCLH in accordance with national and
international guidelines [12, 13]. Samples are processed
within four h of collection and platelet-poor plasma is pre-
pared from blood withdrawn by venepuncture in 0.109 M
sodium citrate 9 : 1, then double-centrifuged at 1500 g for
15 min and stored at 80C immediately after preparation.
LA activity is confirmed in non-anticoagulated samples by
the DRVVT, using Siemens Healthcare (Marburg,
Germany) LA1 (screening) and LA2 (confirmation) re-
agents (Siemens Healthcare (Marburg, Germany). For pa-
tients receiving warfarin, the DRVVT includes testing with
screen and confirm reagents on equal volume mixtures of
patient/normal plasma (which, if positive, confirms the
presence of an inhibitor and phospholipid dependence)
and a Taipan venom time (TVT)/Ecarin clotting time
(Diagnostic Reagents Ltd, Thame, UK) ratio is also per-
formed. The normalized ratio cut-off value for the DRVVT
is 1.20 and for the Taipan venom time/Ecarin clotting time
1.12.
ELISA
The methods for the IgG aCL, IgG anti-b2GPI and IgG
anti-DI ELISAs have been detailed fully in previous
papers [9, 14, 15]. For this study, we had established posi-
tive/negative cut-offs in all three of these ELISAs as the
99th percentile of 40 healthy controls. These levels are 21
GPLU for aCL, 22 GBU for anti-b2GPI and 22 GDIU for
anti-DI.
In this paper we use the term single-ELISA-positive for
any patient positive for either IgG aCL or IgG anti-b2GPI or
IgG anti-DI, double-ELISA-positive for any patient positive
in any two of these ELISAs and triple-ELISA-positive for
any patient positive in all three ELISAs. These terms are
used to make a clear distinction with the terms double and
triple-positive that are generally used in APS to refer to
aCL, anti-b2GPI and LA [3, 4].
Statistical analysis
For the KaplanMeier analysis of mortality, patients were
divided on the basis of serology of the initial sample into
aPL-single-ELISA-positive, aPL double/triple-ELISA posi-
tive and aPL-negative. Patients were censored at the time
of loss to follow-up or at the end of the study period. For
the KaplanMeier analysis of VE, patients were censored
at the time of death, loss to follow-up or the end of the
study period.
Results
For the 501 patients with SLE included in the study, mean
age at the time of sample was 30 years (S.D. 12.2) and
mean follow-up was 12.1 years, with a maximum of
36 years. There were 457 (91%) women and 307 (67%)
Caucasians. For the 40 healthy controls, mean age was
31.3 years (S.D. 7.1), 26 (65%) were women and 33 (83%)
Caucasian. Table 1 shows demographic, clinical and
serological features of these patients.
Prevalence of IgG aCL, IgG anti-b2GPI and IgG
anti-DI positivity at baseline
Of the 501 samples from early disease, 190 (38%) were
positive for one or more of IgG aCL, IgG anti-b2GPI and
IgG anti-DI. A total of 39 patients were double-ELISA-
positive for any of the three aPL, or triple-ELISA positive.
The Venn diagram in Fig. 1 shows how the populations
seropositive for these antibodies overlapped. IgG anti-DI
was the most common antibody found (146/501 patients,
29%) whereas IgG anti-b2GPI was the least common (24/
501, 5%). In fact, 112 patients (22%) were single-positive
for anti-DI alone. Correlation was stronger between aCL
and anti-b2GPI (correlation coefficient = 0.60) than be-
tween anti-DI and anti-b2GPI (0.19) or anti-DI and aCL
(0.12). The mean IgG anti-DI level was higher in those
who were positive for both IgG anti-DI and IgG anti-
b2GPI than in those who were positive for IgG anti-DI
alone (49.5 vs 24.2 GDIU, P= 0.04).
The Sydney criteria [2] use definitions of aCL positivity
higher than ours (>40 GPLU).
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Of 68 patients whose samples were positive for IgG
aCL, 32 had values > 40 GPLU. Of 24 positive for IgG
anti-b2GPI, eight had values > 40GBU. Of 146 IgG anti-
DI-positive patients, 46 had values > 40 GDIU.
Presence of IgG aPL in early disease is strongly
associated with development of LA
In 216 cases, we had data on LA positivity as well as early
aPL serology. Of those, 177 (82%) were LA-negative and
39 (18%) were LA-positive at some point either at diagno-
sis or during the follow-up period. Positivity for any of the
three aPL in the earliest sample was significantly more
common in LA-positive than LA-negative patients [25/39
(64%) vs 55/177 (31%), P= 0.0002]. Furthermore, 9/39
(23%) of LA-positive patients were double-ELISA or
triple-ELISA-positive for IgG aCL, anti-b2GPI and/or anti-
DI in the earliest sample compared with 5/177 (3%) of LA
negative patients (P <0.0001).
Survival analysis of the effect of different antibody
profiles at baseline
Mortality
Of the 501 patients for whom serological data were avail-
able, 67 (13%) had died, of whom 34 were aPL-positive.
Thus 34/190 (17.8%) aPL-positive vs 33/311 (10.6%) aPL-
negative patients had died (P= 0.022 Fisher’s exact test).
Nine patients who died were double-ELISA or triple-
ELISA-positive.
Causes of death in the aPL-positive group were; cancer
12 (35.3%), infection 7 (20.6%), vascular 7 (20.6%), other
8 (23.5%). Causes of death in the aPL-negative group
were; cancer 6 (18.2%), infection 9 (27.3%), vascular 5
(15.2%), other 13 (39.4%).
Fig. 2 shows survival curves for patients divided into
three groups  aPL-negative, single-ELISA-positive and
double/triple-ELISA-positive based on the results in the ini-
tial sample. Fig. 2a includes all deaths whereas Fig. 2b in-
cludes only vascular deaths on the basis that these are
more likely to be linked to aPL. There was no statistically
significant difference between the curves in either figure,
though at time points after 15 years the double/triple-
ELISA curve falls below the others in both figures.
The numbers remaining under follow-up were 438 (168
in the original aPL-positive group) at 5 years, 284 (127) at
10 years, 179 (86) at 15 years, 101 (57) at 20 years, 48 (27)
at 25 years and 25 (16) at 30 years.
Vascular events
We had both aPL serology in the earliest sample and com-
plete history of VE for a sub-group of 276 patients (25
men). Of these patients, 112 (41%) were positive for at
least one of IgG aCL, IgG anti-b2GPI and IgG anti-DI in
the original sample.
Eighty-three of these 276 patients had suffered a VE,
including 43/112 (38%) in the aPL-positive group, 12/21
(57%) in the double/triple-ELISA-positive group and 40/
164 (24%) in the aPL-negative group. The types of VE in
each group are shown in Table 2.
Twenty-five (10 aPL-positive, four double/triple-ELISA-
positive) patients suffered the VE before the date of the
earliest sample and were censored at a value of 0.1 years
in the KaplanMeier analysis. The numbers remaining
TABLE 1 Demographic, clinical and serological features of
patients in this study
Age, mean (S.D.), years
30.0
(12.2)
Range:
177
Female gender 457 91.2%
Ethnicity
Caucasian 309 61.7%
Asian 84 16.8%
African/Caribbean 95 19.0%
Other 13 2.6%
Skin disease
Rash 342 68.3%
Photosensitivity 217 43.3%
Alopecia 132 26.4%
Mouth ulcers 133 26.6%
Joint disease 475 94.8%
Kidney disease 181 36.1%
Serositis 209 41.7%
Central nervous system disease 99 19.8%
Positive anti-dsDNA (ever) 334 66.7%
Low complement (ever) 250 49.9%
Anti-extractable nuclear
antigens (ever positive)
Anti-Sm 76 15.2%
Anti-Ro 197 39.3%
Anti-La 71 14.2%
Anti-RNP 148 29.5%
Rheumatoid factor 124 24.8%
FIG. 1 Prevalence of IgG anti-b2GPI, aCL and anti-DI in
501 samples from patients with SLE
The Venn diagram displays the number of single-ELISA,
double-ELISA and triple-ELISA positive IgG anti-b2GPI,
aCL and anti-DI in 190 patients with SLE. The number of
aPL-negative samples is also shown. anti-b2GPI: anti-
beta-2-glycoprotein I; DI: domain I.
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under follow-up were 210 (92 in the original aPL-positive
group) at 5 years, 122 (59) at 10 years, 73 (42) at 15 years,
35 (27) at 20 years, 15 (12) at 25 years and 8 (7) at 30 years.
Of the 33 aPL-positive patients who suffered VE during
the follow-up period, only three were on anticoagulants
at the time of their first VE, 23 were definitely not antic-
oagulated and for the other seven, this information was
unavailable.
Fig. 3 shows a KaplanMeier graph demonstrating VE
outcomes in different groups of patients stratified by the
FIG. 2 Mortality and vascular mortality over time in patients stratified by serology for aPL
This figure shows survival in all 501 patients in the study over time. Fig. 2a includes all deaths and Fig. 2b includes only
vascular deaths. The x-axis shows time in years.
TABLE 2 Types of VE in different groups of patients
Type of VE
aPL-negative
(n=164) n (%)
Positive for any
aPL (n=112) n (%)
Double or triple ELISA
positive (n=21) n (%)
Any VE 40 (24%) 43 (38%) 12 (57%)
Venous thrombosis alone 19 (12%) 14 (12.5%) 6 (29%)
Stroke alone 12 (7%) 12 (11%) 3 (14%)
IHD alone 6 (4%) 10 (9%) 0
Venous thrombosis and stroke 0 2 (2%) 2 (9.5%)
Venous thrombosis and IHD 0 3 (3%) 1 (5%)
Stroke and IHD 3 (2%) 2 (2%) 0
IHD: ischaemic heart disease; VE: vascular events.
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serology in the earliest sample. The curve comparing
double/triple-ELISA positive patients to the other
groups shows a clear divergence of the curves, with
the double/triple-ELISA group having the worst out-
comes, though the P-value just failed to reach signifi-
cance (P= 0.06). We also compared aPL-positive (any)
to aPL-negative, anti-DI-positive to anti-DI-negative
and high anti-DI positive (>40 GDIU) to low-anti-DI posi-
tive and anti-DI negative and no differences between
groups were seen.
Discussion
The strengths of this analysis are the large number of in-
dividual patients studied and the long-term follow-up of
mortality and VE, as shown in the KaplanMeier analysis.
The major findings were the high proportion of patients
positive for IgG anti-DI in early disease and a trend to-
wards increased risk of developing VE in patients who
were either double or triple-ELISA-positive in early
disease.
The role of testing for anti-DI in diagnosis of APS has
been tested in a number of studies. In a meta-analysis of
11 studies including 1218 patients with APS, 318 patients
with SLE, 49 asymptomatic aPL-positive individuals and
1859 healthy controls, Radin et al. [16] reported that
45.4% of patients with APS were positive for anti-DI and
that four of the five studies that looked at association be-
tween anti-DI-positivity and risk of thrombosis found such
an association, with odds ratios ranging between 2.5 and
4. Other studies, however, have noted inconsistency of
results obtained using different techniques for measuring
anti-DI [17] and concluded that the anti-DI assay does not
add to the predictive value for thrombosis of the combin-
ation of three assays used in current clinical practice
[1720].
A large number of patients in our study tested positive
for IgG anti-DI in samples taken very early in disease.
There are two surprising things about this result. Firstly,
several other papers have shown that IgG anti-DI posi-
tivity is less common than IgG aCL or anti-b2GPI posi-
tivity in patients with SLE [9, 18, 19, 21], leading to the
argument that anti-DI is more specific for APS but less
sensitive [1720]. A different result was obtained by
Wahezi et al. [22] in a population of 183 children with
SLE, of whom 25.1% were IgG anti-DI positive, though
that paper did not report on presence of anti-b2GPI anti-
bodies and only a minority of patients were tested for IgG
aCL.
Secondly, 112 patients in our study were positive for
IgG anti-DI but negative for aCL and anti-b2GPI. There
was very low correlation between IgG anti-b2GPI and
IgG anti-DI titres. This is very different to results obtained
in previous studies in which these antibody specificities
are strongly correlated [18, 19] as would be expected from
the fact that DI is part of b2GPI. For example, De Craemer
et al. [19] tested 426 subjects and found that of 60 who
were IgG anti-b2GPI-positive, 55 were also IgG anti-DI-
positive. Iwaniec et al. [18] tested 103 patients with APS,
99 with SLE and 102 healthy control subjects and found
that of 109 who were IgG anti-b2GPI-positive, 78 were
also IgG anti-DI-positive. Only one patient was IgG anti-
DI-positive but IgG anti- b 2GPI-negative.
One possible explanation for this apparently high level
of isolated anti-DI positivity in our study is that it arises for
methodological reasons. As described by Yin et al. [17] in
a recent review, both IgG anti-b2GPI and IgG anti-DI
assays give variable results depending on factors such
as source of antigen, coating density of antigen and ex-
posure of the immunogenic G40-R43 epitope on DI. Thus,
it is possible that our anti-b2GPI ELISA gives falsely low
results because that epitope is not fully exposed.
Alternatively, if the positive cut-off for IgG anti-DI in this
study (established in a relatively small number of healthy
control subjects) is too low, there might be false-positive
readings. It is impossible to exclude either of these pos-
sibilities completely, although in our paper comparing re-
sults from 111 patients with APS, 119 patients with SLE
and 200 healthy controls, the specificity of the IgG anti-DI
ELISA for APS was 96% [9].
The majority (100/146) of the IgG anti-DI-positive pa-
tients have low positive titres (between 21 and 40 GDIU)
suggesting antibodies of low affinity. Arbuckle et al. [23]
studied samples from 130 American military personnel
that had been stored many years before they were diag-
nosed with SLE and found that autoantibodies were
often present before clinical manifestations of the dis-
ease had developed. aPL were among the earliest spe-
cificities detected. It is possible that early in the disease
course of our 501 patients, low affinity anti-DI antibodies
are present. These antibodies could potentially bind to DI
coated on an ELISA plate much better than whole b2GPI,
where the key epitope on DI is not accessible in all mol-
ecules. As the disease progresses, some patients might
lose these low affinity antibodies altogether, while others
develop higher affinity anti-DI. However, because we do
not have IgG anti-DI data from later time points, this idea
is speculative.
FIG. 3 Incidence of vascular events over time in patients
stratified by serology for aPL
This KaplanMeier curve shows vascular event-free sur-
vival analysis of 276 patients for whom both full vascular
history and aPL results in samples from early disease
were available. Patients were stratified into three groups:
aPL-negative; single-ELISA-positive; and double/triple-
ELISA-positive. The x-axis shows time in years.
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Although this study shows that 38% (190/501) of pa-
tients had at least one of these three aPL very early in
disease, the analysis does not suggest that aPL-positivity
per se predicts clinical outcomes. KaplanMeier analysis
of mortality or vascular mortality did not show significant
differences between aPL-positive and aPL-negative pa-
tients and causes of death in aPL-positive patients were
not skewed towards VE.
The one subgroup of patients identified as having a po-
tentially worse long-term outlook in this study were those
who tested positive for either two or three of IgG aCL,
anti-b2GPI and anti-DI early in disease. There were 39
such patients, but if anti-DI had not been tested, only 14
of these would have been identified (i.e. aCL plus anti-
b2GPI positive). The KaplanMeier curves suggest that
this double/triple-ELISA positive group do worse in
terms of vascular outcomes, but this result cannot be
over-interpreted because even in this large group of pa-
tients, the results did not reach statistical significance.
There was, however, a strong association between
double/triple-ELISA positivity and LA. Pengo et al. [24]
noted that while there are some patients who test LA-
positive but anti-b2GPI negative (due to presence of IgM
anti-phosphatidylserine/prothrombin antibodies), those
positive in both assays have a much higher risk of
thrombosis.
Limitations include the fact that this study is
cross-sectional, with ELISA data for a single time-point
for each patient, and that VE were recorded retrospect-
ively from patients’ charts and interviews. It is not possible
to test LA in stored serum samples because of the method
used in the LA assay, which requires the blood to clot.
Only IgG isotype antibodies were tested. In future studies
it would be of interest to obtain samples taken from these
same serological groups of patients at later dates to
assess the extent to which single, double and triple-
ELISA positivity remain stable over time.
In summary, IgG anti-DI antibodies were found in early
serum samples from 29% of 501 patients with SLE and
were more commonly detected than IgG anti-b2GPI and
aCL. There was no strong evidence that testing for IgG
anti-DI in early disease would alter management of pa-
tients with SLE.
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